EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Pharmacokinetics and pharmacodynamics of high-dose isoniazid for the treatment of rifampicin- or multidrug-resistant tuberculosis in Indonesia

Vycke Yunivita, Fajri Gafar, Prayudi Santoso, Lidya Chaidir, Arto Y Soeroto, Triana N Meirina, Lindsey Te Brake, Dick Menzies, Rob E Aarnoutse, Rovina Ruslami iD

Journal of Antimicrobial Chemotherapy · 2024

DOI: 10.1093/jac/dkae057 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Vycke Yunivita und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacology and Therapy, Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia. Hauptthemen laut MEDLINE: Isoniazid, Rifampin, Antitubercular Agents, Tuberculosis, Multidrug-Resistant. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Universitas Padjadjaran.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pharmacokinetic data on high-dose isoniazid for the treatment of rifampicin-/multidrug-resistant tuberculosis (RR/MDR-TB) are limited. We aimed to describe the pharmacokinetics of high-dose isoniazid, estimate exposure target attainment, identify predictors of exposures, and explore exposure–response relationships in RR/MDR-TB patients.

Methods

We performed an observational pharmacokinetic study, with exploratory pharmacokinetic/pharmacodynamic analyses, in Indonesian adults aged 18–65 years treated for pulmonary RR/MDR-TB with standardized regimens containing high-dose isoniazid (10–15 mg/kg/day) for 9–11 months. Intensive pharmacokinetic sampling was performed after ≥2 weeks of treatment. Total plasma drug exposure (AUC0–24) and peak concentration (Cmax) were assessed using non-compartmental analyses. AUC0–24/MIC ratio of 85 and Cmax/MIC ratio of 17.5 were used as exposure targets. Multivariable linear and logistic regression analyses were used to identify predictors of drug exposures and responses, respectively.

Results

We consecutively enrolled 40 patients (median age 37.5 years). The geometric mean isoniazid AUC0–24 and Cmax were 35.4 h·mg/L and 8.5 mg/L, respectively. Lower AUC0–24 and Cmax values were associated (P < 0.05) with non-slow acetylator phenotype, and lower Cmax values were associated with male sex. Of the 26 patients with MIC data, less than 25% achieved the proposed targets for isoniazid AUC0–24/MIC (n = 6/26) and Cmax/MIC (n = 5/26). Lower isoniazid AUC0–24 values were associated with delayed sputum culture conversion (>2 months of treatment) [adjusted OR 0.18 (95% CI 0.04–0.89)].

Conclusions

Isoniazid exposures below targets were observed in most patients, and certain risk groups for low isoniazid exposures may require dose adjustment. The effect of low isoniazid exposures on delayed culture conversion deserves attention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IsoniazidRifampinAntitubercular AgentsTuberculosis, Multidrug-ResistantMicrobial Sensitivity TestsHumansAdultMaleFemaleMiddle AgedIndonesiaYoung AdultAdolescentAgedTuberculosis, PulmonaryMycobacterium tuberculosis

Substanzen

IsoniazidRifampinAntitubercular Agents

Autor:innen und Institutionen

  • Division of Pharmacology and Therapy, Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia.
  • TB Working Group, Research Center for Care and Control of Infectious Diseases, Universitas Padjadjaran, Bandung, Indonesia.
  • Respiratory Epidemiology and Clinical Research Unit, Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, 5252 Boulevard de Maisonneuve Ouest, Office 3D.21, Montreal, Q…
  • McGill International TB Centre, McGill University, Montreal, Quebec, Canada.
  • Division of Respirology and Critical Care, Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran and Hasan Sadikin General Hospital, Bandung, Indonesia.
  • Division of Microbiology, Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia.

ORCID-Profile: Rovina Ruslami

Förderung

  • Universitas Padjadjaran

Zitieren

APA

Yunivita, V., Gafar, F., Santoso, P., Chaidir, L., Soeroto, A. Y., Meirina, T. N., Te Brake, L., Menzies, D., Aarnoutse, R. E., & Ruslami, R. (2024). Pharmacokinetics and pharmacodynamics of high-dose isoniazid for the treatment of rifampicin- or multidrug-resistant tuberculosis in Indonesia. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae057

Vancouver

Yunivita V, Gafar F, Santoso P, Chaidir L, Soeroto AY, Meirina TN, et al. Pharmacokinetics and pharmacodynamics of high-dose isoniazid for the treatment of rifampicin- or multidrug-resistant tuberculosis in Indonesia. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae057

BibTeX
@article{Yunivita2024,
  author = {Yunivita, Vycke and Gafar, Fajri and Santoso, Prayudi and Chaidir, Lidya and Soeroto, Arto Y and Meirina, Triana N and Te Brake, Lindsey and Menzies, Dick and Aarnoutse, Rob E and Ruslami, Rovina},
  title = {Pharmacokinetics and pharmacodynamics of high-dose isoniazid for the treatment of rifampicin- or multidrug-resistant tuberculosis in Indonesia},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  doi = {10.1093/jac/dkae057}
}
Kostenlos starten →